Report: Alkermes ’ ALKS-5461 to emerge as key player in major depressive disorder market

Positive results from a Phase III study on Alkermes ’ ALKS-5461 shows promise towards the development of a new treatment for major depressive disorder (MDD), according to a report by GlobalData.

Source: Drug Development Technology - November 11, 2016 Category: Pharmaceuticals Source Type: news